129 related articles for article (PubMed ID: 28858981)
1. Individualizing treatment choices in the systolic blood pressure intervention trial.
Ferreira JP; Gregson J; Duarte K; Gueyffier F; Rossignol P; Zannad F; Pocock S
J Hypertens; 2018 Feb; 36(2):428-435. PubMed ID: 28858981
[TBL] [Abstract][Full Text] [Related]
2. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
[TBL] [Abstract][Full Text] [Related]
3. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.
Williamson JD; Supiano MA; Applegate WB; Berlowitz DR; Campbell RC; Chertow GM; Fine LJ; Haley WE; Hawfield AT; Ix JH; Kitzman DW; Kostis JB; Krousel-Wood MA; Launer LJ; Oparil S; Rodriguez CJ; Roumie CL; Shorr RI; Sink KM; Wadley VG; Whelton PK; Whittle J; Woolard NF; Wright JT; Pajewski NM;
JAMA; 2016 Jun; 315(24):2673-82. PubMed ID: 27195814
[TBL] [Abstract][Full Text] [Related]
4. Impact of cumulative SBP and serious adverse events on efficacy of intensive blood pressure treatment: a randomized clinical trial.
Rueda-Ochoa OL; Rojas LZ; Ahmad S; van Duijn CM; Ikram MA; Deckers JW; Franco OH; Rizopoulos D; Kavousi M
J Hypertens; 2019 May; 37(5):1058-1069. PubMed ID: 30444838
[TBL] [Abstract][Full Text] [Related]
5. Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).
Bress AP; Kramer H; Khatib R; Beddhu S; Cheung AK; Hess R; Bansal VK; Cao G; Yee J; Moran AE; Durazo-Arvizu R; Muntner P; Cooper RS
Circulation; 2017 Apr; 135(17):1617-1628. PubMed ID: 28193605
[TBL] [Abstract][Full Text] [Related]
6. Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial.
Byrne C; Pareek M; Vaduganathan M; Biering-Sørensen T; Qamar A; Pandey A; Olesen TB; Olsen MH; Bhatt DL
Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):356-363. PubMed ID: 31529024
[TBL] [Abstract][Full Text] [Related]
7. Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension from the Systolic Blood Pressure Intervention Trial.
Foy CG; Lovato LC; Vitolins MZ; Bates JT; Campbell R; Cushman WC; Glasser SP; Gillespie A; Kostis WJ; Krousel-Wood M; Muhlestein JB; Oparil S; Osei K; Pisoni R; Segal MS; Wiggers A; Johnson KC;
J Hypertens; 2018 Apr; 36(4):904-915. PubMed ID: 29493562
[TBL] [Abstract][Full Text] [Related]
8. Personalizing the Intensity of Blood Pressure Control: Modeling the Heterogeneity of Risks and Benefits From SPRINT (Systolic Blood Pressure Intervention Trial).
Patel KK; Arnold SV; Chan PS; Tang Y; Pokharel Y; Jones PG; Spertus JA
Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28373269
[TBL] [Abstract][Full Text] [Related]
9. Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial.
Upadhya B; Rocco M; Lewis CE; Oparil S; Lovato LC; Cushman WC; Bates JT; Bello NA; Aurigemma G; Fine LJ; Johnson KC; Rodriguez CJ; Raj DS; Rastogi A; Tamariz L; Wiggers A; Kitzman DW;
Circ Heart Fail; 2017 Apr; 10(4):. PubMed ID: 28364091
[TBL] [Abstract][Full Text] [Related]
10. Incremental effects of antihypertensive drugs: instrumental variable analysis.
Markovitz AA; Mack JA; Nallamothu BK; Ayanian JZ; Ryan AM
BMJ; 2017 Dec; 359():j5542. PubMed ID: 29273586
[TBL] [Abstract][Full Text] [Related]
11. Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events.
Bress AP; Greene T; Derington CG; Shen J; Xu Y; Zhang Y; Ying J; Bellows BK; Cushman WC; Whelton PK; Pajewski NM; Reboussin D; Beddu S; Hess R; Herrick JS; Zhang Z; Kolm P; Yeh RW; Basu S; Weintraub WS; Moran AE;
J Am Coll Cardiol; 2021 Apr; 77(16):1977-1990. PubMed ID: 33888247
[TBL] [Abstract][Full Text] [Related]
12. Impact of Cardiovascular Risk on the Relative Benefit and Harm of Intensive Treatment of Hypertension.
Phillips RA; Xu J; Peterson LE; Arnold RM; Diamond JA; Schussheim AE
J Am Coll Cardiol; 2018 Apr; 71(15):1601-1610. PubMed ID: 29525494
[TBL] [Abstract][Full Text] [Related]
13. Association of Acute Kidney Injury with Cardiovascular Events and Death in Systolic Blood Pressure Intervention Trial.
Dieter BP; Daratha KB; McPherson SM; Short R; Alicic RZ; Tuttle KR
Am J Nephrol; 2019; 49(5):359-367. PubMed ID: 30939480
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of blood pressure-lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).
Zhang L; Sun X; Liao L; Zhang S; Zhou H; Zhong X; Zhuang X; Liao X
J Clin Hypertens (Greenwich); 2019 Dec; 21(12):1813-1820. PubMed ID: 31670874
[TBL] [Abstract][Full Text] [Related]
15. [The SPRINT Research. A Randomized Trial of Intensive versus Standard Blood-Pressure Control].
Widimský J
Vnitr Lek; 2016 Jan; 62(1):44-7. PubMed ID: 26967236
[TBL] [Abstract][Full Text] [Related]
16. Blood Pressure Variability Predicts Adverse Events and Cardiovascular Outcomes in Chronic Kidney Disease: A Post-Hoc Analysis of the SPRINT Trial.
Mezue K; Goyal A; Pressman GS; Horrow JC; Rangaswami J
Am J Hypertens; 2017 Dec; 31(1):48-52. PubMed ID: 28985328
[TBL] [Abstract][Full Text] [Related]
17. More Versus Less Intensive Blood Pressure-Lowering Strategy: Cumulative Evidence and Trial Sequential Analysis.
Verdecchia P; Angeli F; Gentile G; Reboldi G
Hypertension; 2016 Sep; 68(3):642-53. PubMed ID: 27456518
[TBL] [Abstract][Full Text] [Related]
18. Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study.
Beatty AL; Ku IA; Bibbins-Domingo K; Christenson RH; DeFilippi CR; Ganz P; Ix JH; Lloyd-Jones D; Omland T; Sabatine MS; Schiller NB; Shlipak MG; Skali H; Takeuchi M; Vittinghoff E; Whooley MA
J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26150476
[TBL] [Abstract][Full Text] [Related]
19. Serious Adverse Events Cluster in Participants Experiencing the Primary Composite Cardiovascular Endpoint: A Post Hoc Analysis of the SPRINT Trial.
Botchway A; Buhnerkempe MG; Prakash V; Al-Akchar M; Adekola B; Flack JM
Am J Hypertens; 2020 May; 33(6):528-533. PubMed ID: 31930338
[TBL] [Abstract][Full Text] [Related]
20. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
